Coya Therapeutics (NASDAQ:COYA) vs. Evogene (NASDAQ:EVGN) Head-To-Head Survey

Evogene (NASDAQ:EVGN – Get Free Report) and Coya Therapeutics (NASDAQ:COYA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Evogene and Coya Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evogene -694.18% -156.53% -86.80%
Coya Therapeutics -643.44% -71.48% -63.57%

Insider & Institutional Ownership

10.4% of Evogene shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Evogene and Coya Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evogene $3.85 million 0.79 -$8.48 million ($0.91) -0.38
Coya Therapeutics $7.95 million 9.12 -$21.23 million ($1.39) -2.22

Evogene has higher earnings, but lower revenue than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Evogene and Coya Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evogene 1 0 0 0 1.00
Coya Therapeutics 1 0 5 0 2.67

Coya Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 385.44%. Given Coya Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Evogene.

Risk and Volatility

Evogene has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Summary

Coya Therapeutics beats Evogene on 9 of the 13 factors compared between the two stocks.

About Evogene

(Get Free Report)

Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.